- Last edited on October 12, 2023
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
geri:dementia:vascular [on February 9, 2022] psychdb [Primer] |
geri:dementia:vascular [on October 12, 2023] psychdb |
||
|---|---|---|---|
| Line 229: | Line 229: | ||
| ==== Pharmacotherapy ==== | ==== Pharmacotherapy ==== | ||
| - | Acetylcholinesterase inhibitors ([[meds:dementia:donepezil|donepezil]], [[meds:dementia:rivastigmine|rivastigmine]], and [[meds:dementia:galantamine|galantamine]]) as a class are modestly efficacious for patients with mixed AD and vascular dementia pathology, and a trial of these medications is recommended for most patients diagnosed with AD.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])] However, in //isolated// vascular dementia, there is insufficient and inconsistent evidence support on whether acetylcholinesterase inhibitors are effective.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])] | + | * Acetylcholinesterase inhibitors ([[meds:dementia:donepezil|donepezil]], [[meds:dementia:rivastigmine|rivastigmine]], and [[meds:dementia:galantamine|galantamine]]) as a class are modestly efficacious for patients with mixed AD and vascular dementia pathology, and a trial of these medications is recommended for most patients diagnosed with AD.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])] |
| + | * However, in //isolated// vascular dementia, there is insufficient and inconsistent evidence support on whether acetylcholinesterase inhibitors are effective.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980908/|Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's research & therapy, 5(1), S5.]])] | ||
| <panel type="info" title="Pharmacotherapy for Vascular Dementia" subtitle="Ritter, A., and Pillai, J. A. (2015). Treatment of vascular cognitive impairment. Current treatment options in neurology, 17(8), 35." no-body="true" footer=""> | <panel type="info" title="Pharmacotherapy for Vascular Dementia" subtitle="Ritter, A., and Pillai, J. A. (2015). Treatment of vascular cognitive impairment. Current treatment options in neurology, 17(8), 35." no-body="true" footer=""> | ||